News and Press Releases
IBSA UK&I assumes direct commercial responsibility for ialuril in the UK and Ireland
Transition supports continuity of supply and aligns ialuril with IBSA’s expanding UK uro-gynaecology portfolio 9 April 2026 -- Watford, UK -- IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company...
Category: BioManufacturing, Other, Pharmaceutical
Posted: April 9, 2026
NICE Recommends TEPKINLY▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy
Epcoritamab can now be accessed as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped...
Category: Drug Discovery, Other, Pharmaceutical
Posted: February 23, 2026
Jemperli®▼(dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer
Jemperli (dostarlimab) with platinum-based chemotherapy to be made available on the NHS for all eligible patients in England for first-line treatment of primary advanced or recurrent endometrial cancer Following a...
Category: Drug Delivery, Other, Pharmaceutical
Posted: November 25, 2025
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 6, 2025
Northern Gritstone invests in Manchester spinout Apini
Northern Gritstone has committed £1.8 million to Apini, a spinout from the University of Manchester Apini is a novel small molecule therapeutic programme for the treatment of multiple chronic inflammatory...
Category: Biotechnology, Other, Pharmaceutical
Posted: June 11, 2025
No.1 Circle Square 3 Symphony Park Manchester M1 7FS
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
21 May 2025 -- Surrey, UK -- Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final draft guidance which recommends Hympavzi (marstacimab)...
Category: Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2025
Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease
Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
TREMFYA (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 28 March 2025 -- Beerse, Belgium -- Johnson & Johnson today announced that...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 28, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Carbon Minimal pressurised Metered Dose Inhalers (pMDIs) could save up to 619,000 tonnes of emissions each year, representing up to 7%-10% of NHS Net Zero targets
At a national level, seamless transitioning to a range of carbon minimal pMDIs could save between 415,000 and 619,000 tCO₂e annually, reducing carbon emissions to the equivalent financial value of...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 10, 2025
NHS patients receive medicines manufactured by Octapharma using UK-donated plasma for the first time in almost 30 years
The sole manufacturer for the UK’s Plasma for Medicines (PfM) programme is supporting the Department of Health and Social Care, NHS England, and NHS Blood and Transplant to build resilience...
Category: Other, Pharmaceutical
Posted: March 6, 2025
Medicines manufacturing skills project uses Virtual Reality to help NHS reach net zero
Resilience, a UK government initiative, says its use of VR will reduce travel and waste 10 February 2025 – The recently launched government-funded medicines manufacturing skills project, Resilience, has said...
Category: Manufacturing and Packing
Posted: February 11, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties 7 January 2025 -- California, US -- Capsida Biotherapeutics today announced that AbbVie has...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 7, 2025
Ingenza announces move to purpose-built facilities to expand fermentation and research capacity
1 October 2024 – Roslin, Scotland – Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate...
Category: BioManufacturing
Posted: October 14, 2024
Ingenza Ltd, Roslin Innovation Centr,e Charnock Bradley Building, Easter Bush Campus, Bush Farm Road, Roslin, EH25 9RG, UK
